Current guidelines recommend 12-month dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor for patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) [1, 2]. The gene discussed is P2RY12; the disease is acute coronary syndrome.